Table 2.
Correlation of cfDNA PIK3CA mutations with AR and pAR
| Variables | Number of cases (%) | ||||||
|---|---|---|---|---|---|---|---|
| Total | AR | pAR | |||||
| PIK3CA mutation of cfDNA | (N = 49) | Positive | Negative | P‐value | Positive | Negative | P‐value |
| (N = 19) | (N = 30) | (N = 12) | (N = 37) | ||||
| Total | 12 | 5 (26.3) | 7 (23.3) | 0.81 | 6 (50) | 6 (16.2) | 0.018† |
| Wild type | 37 | 14 (73.7) | 23 (76.7) | 6 (50) | 31 (83.8) | ||
| Kinase domain (H1047R) | 7 | 3 (15.8) | 4 (13.3) | 0.81 | 3 (25) | 4 (10.8) | 0.22 |
| Others | 42 | 16 (84.2) | 26 (86.7) | 9 (75) | 33 (89.2) | ||
| Helical domain (E542K, E545K) | 7 | 3 (15.8) | 4 (13.3) | 0.81 | 4 (33.3) | 3 (8.1) | 0.03† |
| Others | 42 | 16 (84.2) | 26 (86.7) | 8 (66.7) | 34 (91.9) | ||
†Factor showing statistical significance. AR, androgen receptor; cfDNA, cell‐free DNA; gDNA; genomic DNA; pAR, AR phosphorylation at serine‐213/210.